Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 1
2012 1
2014 1
2021 1
2022 2
2023 1
2024 4
2025 4
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Weight gain, body composition, and metabolic parameters of dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: an ancillary analysis of the ODYSSEY trial.
Turkova A, White E, Violari A, Mujuru HA, Kekitiinwa AR, Lugemwa A, Kaudha E, Na-Rajsima S, Ahimbisibwe GM, Variavae E, Archary M, Akhalwaya Y, Puthanakit T, Bwakura-Dangarembizi M, Bbuye D, Kasozi M, Liberty A, Königs C, Welch SB, Riault Y, Bamford A, Cressey TR, Musoke P, Kityo C, Ferrand R, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2026 Jan 21:S2352-4642(25)00339-6. doi: 10.1016/S2352-4642(25)00339-6. Online ahead of print. Lancet Child Adolesc Health. 2026. PMID: 41579881 Free article.
Once-daily dolutegravir/lamivudine fixed-dose formulations in children living with HIV: a pharmacokinetic and safety sub-study nested in the open-label, multicentre, randomised, non-inferiority D3/PENTA 21 trial.
Bevers LAH, Toledo G, Kisekka M, Kaudha E, Ahimbisibwe GM, Deprez I, Arumugan T, Variava E, Violari A, White I, Bbuye D, Nanduudu A, Mulwanyi E, Amuge P, Rutebarika DA, Kekitiinwa A, Kityo C, Musoke P, Archary M, Boles J, Thomason MJ, de Wildt SN, Giaquinto C, Colbers A, Burger DM, Buchanan AM, Chan MK, Jacobs TG, Turkova A; D3 TRIAL TEAM. Bevers LAH, et al. Among authors: rutebarika da. EBioMedicine. 2025 Oct;120:105929. doi: 10.1016/j.ebiom.2025.105929. Epub 2025 Sep 26. EBioMedicine. 2025. PMID: 41014973 Free PMC article. Clinical Trial.
Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV.
Tsirizani L, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, McIlleron HM, Burger DM, Gibb DM, Colbers A, Denti P, Wasmann RE; CHAPAS-4 trial team. Tsirizani L, et al. Among authors: rutebarika da. Antimicrob Agents Chemother. 2025 Nov 5;69(11):e0077125. doi: 10.1128/aac.00771-25. Epub 2025 Sep 26. Antimicrob Agents Chemother. 2025. PMID: 41004270 Free PMC article. Clinical Trial.
BREATHER Plus clinical trial design: A randomised non-inferiority trial evaluating the efficacy, safety and acceptability of short cycle (five days on, two days off) dolutegravir/tenofovir-based triple antiretroviral therapy (ART) compared to daily ART in virologically suppressed adolescents living with HIV aged 12 to <20 years in sub-Saharan Africa.
Katongole F, Arumugam T, Jennings A, Mutata C, Ssebunya P, Wamboi C, Green A, Bwakura-Dangarembizi M, Kityo C, Siika A, Archary M, Jafta L, Namukwaya S, Seeley J, Mugerwa H, Walker S, Apoto N, Thomason MJ, Ford D, Pett SL, Kekitiinwa AR; BREATHER Plus trial team. Katongole F, et al. Contemp Clin Trials. 2025 Aug;155:107963. doi: 10.1016/j.cct.2025.107963. Epub 2025 May 29. Contemp Clin Trials. 2025. PMID: 40449658 Free PMC article.
Safety and efficacy of iron supplementation with 3 months of daily ferrous sulphate in children living with HIV and mild-to-moderate anaemia in Uganda: a double-blind, randomised, placebo-controlled trial.
Frosch AEP, Musiime V, Staley C, Conroy AL, Rutebarika D, Ategeka G, Cusick SE. Frosch AEP, et al. Among authors: rutebarika d. Lancet HIV. 2024 Nov;11(11):e727-e735. doi: 10.1016/S2352-3018(24)00238-8. Epub 2024 Oct 11. Lancet HIV. 2024. PMID: 39401504 Free PMC article. Clinical Trial.
Pharmacokinetics of once-daily darunavir/ritonavir in second-line treatment in African children with HIV.
Tsirizani L, Mohsenian Naghani S, Waalewijn H, Szubert A, Mulenga V, Chabala C, Bwakura-Dangarembizi M, Chitsamatanga M, Rutebarika DA, Musiime V, Kasozi M, Lugemwa A, Monkiewicz LN, McIlleron HM, Burger DM, Gibb DM, Denti P, Wasmann RE, Colbers A. Tsirizani L, et al. Among authors: rutebarika da. J Antimicrob Chemother. 2024 Nov 4;79(11):2990-2998. doi: 10.1093/jac/dkae319. J Antimicrob Chemother. 2024. PMID: 39302766 Free PMC article. Clinical Trial.
Correction: Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers.
Amuge PM, Ndekezi D, Mugerwa M, Bbuye D, Rutebarika DA, Kizza L, Namugwanya C, Baita A, Elyanu PJ, Ntege PN, Kiragga D, Birungi C, Kekitiinwa AR, Kiragga A, Sekadde MP, Salazar-Austin N, Mandalakas AM, Musoke P. Amuge PM, et al. Among authors: rutebarika da. AIDS Res Ther. 2024 Sep 6;21(1):61. doi: 10.1186/s12981-024-00651-2. AIDS Res Ther. 2024. PMID: 39243090 Free PMC article. No abstract available.
Facilitators and barriers to initiating and completing tuberculosis preventive treatment among children and adolescents living with HIV in Uganda: a qualitative study of adolescents, caretakers and health workers.
Amuge PM, Ndekezi D, Mugerwa M, Bbuye D, Rutebarika DA, Kizza L, Namugwanya C, Baita A, Elyanu PJ, Ntege PN, Kiragga D, Birungi C, Kekitiinwa AR, Kiragga A, Sekadde MP, Salazar NA, Mandalakas AM, Musoke P. Amuge PM, et al. Among authors: rutebarika da. AIDS Res Ther. 2024 Aug 29;21(1):59. doi: 10.1186/s12981-024-00643-2. AIDS Res Ther. 2024. PMID: 39210349 Free PMC article.
Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial.
Turkova A, White E, Kekitiinwa AR, Mumbiro V, Kaudha E, Liberty A, Ahimbisibwe GM, Moloantoa T, Srirompotong U, Mosia NR, Puthanakit T, Kobbe R, Fortuny C, Kataike H, Bbuye D, Na-Rajsima S, Coelho A, Lugemwa A, Bwakura-Dangarembizi MF, Klein N, Mujuru HA, Kityo C, Cotton MF, Ferrand RA, Giaquinto C, Rojo P, Violari A, Gibb DM, Ford D; ODYSSEY trial team. Turkova A, et al. Lancet Child Adolesc Health. 2023 Oct;7(10):718-727. doi: 10.1016/S2352-4642(23)00164-5. Epub 2023 Aug 8. Lancet Child Adolesc Health. 2023. PMID: 37562418 Free PMC article. Clinical Trial.
17 results